You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZiprasidone
Accession NumberDB00246  (APRD00540)
TypeSmall Molecule
GroupsApproved
Description

Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia]

Structure
Thumb
Synonyms
Ziprasidona
Ziprasidone
Ziprasidonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-ziprasidonecapsule40 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidonecapsule80 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidonecapsule20 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-ziprasidonecapsule60 mgoralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Geodoncapsule80 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule80 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoncapsule80 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoncapsule80 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule40 mg/1oralRoerig2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralUnit Dose Services2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoncapsule20 mg/1oralRoerig2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-27Not applicableUs
Geodoncapsule40 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularRoerig2003-12-23Not applicableUs
Geodoncapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-05Not applicableUs
Geodoncapsule20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Geodoncapsule20 mg/1oralRebel Distributors Corp2001-02-05Not applicableUs
Geodoncapsule80 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule80 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularTYA Pharmaceuticals2003-12-23Not applicableUs
Geodoncapsule20 mg/1oralSTAT Rx USA LLC2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoncapsule40 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule60 mg/1oralRoerig2013-11-01Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularREMEDYREPACK INC.2015-02-13Not applicableUs
Geodoncapsule80 mg/1oralRoerig2001-02-05Not applicableUs
Geodoncapsule40 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoncapsule20 mg/1oralCardinal Health2001-02-05Not applicableUs
Geodoncapsule20 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Geodoninjection, powder, lyophilized, for solution20 mg/mLintramuscularCardinal Health2003-12-23Not applicableUs
Geodoncapsule40 mg/1oralRoerig2013-11-01Not applicableUs
Geodoncapsule60 mg/1oralRoerig2001-02-05Not applicableUs
Zeldoxcapsule80 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Zeldoxcapsule60 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Zeldoxcapsule40 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Zeldoxcapsule20.0 mgoralPfizer Canada Inc2008-01-04Not applicableCanada
Ziprasidonecapsule60 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Ziprasidonecapsule40 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Ziprasidonecapsule20 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Ziprasidonecapsule40 mg/1oralREMEDYREPACK INC.2013-05-02Not applicableUs
Ziprasidonecapsule60 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Ziprasidonecapsule20 mg/1oralREMEDYREPACK INC.2013-01-04Not applicableUs
Ziprasidonecapsule80 mg/1oralGreenstone LLC2001-02-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ziprasidone Hydrochloridecapsule60 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2016-02-10Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralREMEDYREPACK INC.2016-02-25Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralCardinal Health2013-07-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralTYA Pharmaceuticals2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralREMEDYREPACK INC.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralTYA Pharmaceuticals2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralUnit Dose Services2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2014-04-25Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralProficient Rx LP2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralREMEDYREPACK INC.2013-02-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralTYA Pharmaceuticals2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralREMEDYREPACK INC.2014-11-12Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2014-03-03Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralMajor Pharmaceuticals2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2014-10-30Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralLUPIN LIMITED2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralCardinal Health2012-03-15Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralLupin Pharmaceuticals, Inc.2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralSandoz Inc2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralREMEDYREPACK INC.2014-10-21Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralTYA Pharmaceuticals2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralClinical Solutions Wholesale2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralProficient Rx LP2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralREMEDYREPACK INC.2016-02-10Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMylan Pharmaceuticals Inc.2014-06-24Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralDr. Reddy's Laboratories Limited2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralGolden State Medical Supply, Inc.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralWockhardt USA LLC.2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralAmerican Health Packaging2014-12-04Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralREMEDYREPACK INC.2016-03-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralRebel Distributors Corp2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralWockhardt Limited2012-09-01Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralApotex Corp.2012-05-14Not applicableUs
Ziprasidone Hydrochloridecapsule20 mg/1oralTYA Pharmaceuticals2013-02-13Not applicableUs
Ziprasidone Hydrochloridecapsule80 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-02Not applicableUs
Ziprasidone Hydrochloridecapsule40 mg/1oralMylan Institutional Inc.2014-09-30Not applicableUs
Ziprasidone Hydrochloridecapsule60 mg/1oralSandoz Inc2013-02-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ziprasidone hydrochloride
Thumb
  • InChI Key: ZCBZSCBNOOIHFP-UHFFFAOYSA-N
  • Monoisotopic Mass: 466.099702136
  • Average Mass: 467.412
DBSALT000810
Ziprasidone mesylate trihydrate
Thumb
  • InChI Key: WLQZEFFFIUHSJB-UHFFFAOYSA-N
  • Monoisotopic Mass: 562.132268453
  • Average Mass: 563.087
DBSALT000811
Categories
UNII6UKA5VEJ6X
CAS number146939-27-7
WeightAverage: 412.936
Monoisotopic: 412.112459711
Chemical FormulaC21H21ClN4OS
InChI KeyMVWVFYHBGMAFLY-UHFFFAOYSA-N
InChI
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
IUPAC Name
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
SMILES
ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenethylamine
  • Dihydroindole
  • Indole or derivatives
  • 1,2-benzothiazole
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • Chlorobenzene
  • Imidolactam
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
PharmacodynamicsZiprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Ziprasidone acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Ziprasidone. Ziprasidone's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Ziprasidone functions as an antagonist at the Dopamine D2 , 5HT-2A , and 5HT-1D receptors, and as an agonist at the 5HT-1A receptor. Ziprasidone also inhibits synaptic reuptake of serotonin and norepinephrine.
Mechanism of actionZiprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.
Related Articles
Absorption~60%
Volume of distribution
  • 1.5 L/kg
Protein binding99%
Metabolism

Hepatic

SubstrateEnzymesProduct
Ziprasidone
benzisothiazole piperazineDetails
Route of eliminationZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.
Half life7 hours
Clearance
  • 7.5 mL/min/kg
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9759
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7167
P-glycoprotein inhibitor IInhibitor0.8052
P-glycoprotein inhibitor IIInhibitor0.6419
Renal organic cation transporterInhibitor0.5325
CYP450 2C9 substrateNon-substrate0.7972
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6576
CYP450 2C9 inhibitorInhibitor0.6329
CYP450 2D6 inhibitorNon-inhibitor0.7151
CYP450 2C19 inhibitorInhibitor0.8086
CYP450 3A4 inhibitorNon-inhibitor0.7723
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9567
Ames testNon AMES toxic0.6273
CarcinogenicityNon-carcinogens0.8672
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6826
hERG inhibition (predictor II)Inhibitor0.7753
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
Capsuleoral20 mg
Capsuleoral20 mg/1
Capsuleoral40 mg/1
Capsuleoral60 mg/1
Capsuleoral80 mg/1
Injection, powder, lyophilized, for solutionintramuscular20 mg/mL
Capsuleoral20.0 mg
Capsuleoral40 mg
Capsuleoral60 mg
Capsuleoral80 mg
Prices
Unit descriptionCostUnit
Zoladex 10.8 mg Implant Syringe1407.72USD syringe
Geodon 20 mg vial16.22USD vial
Geodon 60 mg capsule9.88USD capsule
Geodon 80 mg capsule9.88USD capsule
Geodon 20 mg capsule8.14USD capsule
Geodon 40 mg capsule8.14USD capsule
Zeldox 40 mg Capsule2.13USD capsule
Zeldox 60 mg Capsule2.13USD capsule
Zeldox 80 mg Capsule2.13USD capsule
Zeldox 20 mg Capsule1.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2105114 No2000-02-152013-08-30Canada
CA2256227 No2003-07-012018-12-16Canada
US5134127 No1993-01-232010-01-23Us
US6110918 No1997-03-262017-03-26Us
US6150366 No1999-05-272019-05-27Us
US6232304 No1997-04-012017-04-01Us
US6245766 No1998-12-182018-12-18Us
US6399777 No1997-04-012017-04-01Us
US7175855 No2000-05-182020-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point>300 °CNot Available
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00718 mg/mLALOGPS
logP4.64ALOGPS
logP4.3ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.18ChemAxon
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.72 m3·mol-1ChemAxon
Polarizability44.96 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Frank R. Busch, Carol A. Rose, “Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist.” U.S. Patent US6110918, issued January, 1995.

US6110918
General References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]
External Links
ATC CodesN05AE04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (75 KB)
MSDSDownload (57.8 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ziprasidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Ziprasidone.
AmisulprideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziprasidone.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ziprasidone.
AmphetamineZiprasidone may decrease the stimulatory activities of Amphetamine.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Ziprasidone.
AzelastineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ziprasidone.
BenzphetamineZiprasidone may decrease the stimulatory activities of Benzphetamine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ziprasidone.
BuprenorphineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziprasidone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ziprasidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
CarbamazepineThe serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.
CarbidopaThe therapeutic efficacy of Carbidopa can be decreased when used in combination with Ziprasidone.
CathinoneZiprasidone may decrease the stimulatory activities of Cathinone.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.
CitalopramCitalopram may increase the QTc-prolonging activities of Ziprasidone.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ziprasidone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziprasidone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziprasidone.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ziprasidone.
DextroamphetamineZiprasidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ziprasidone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ziprasidone.
DofetilideDofetilide may increase the QTc-prolonging activities of Ziprasidone.
DonepezilDonepezil may increase the central neurotoxic activities of Ziprasidone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziprasidone.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ziprasidone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ziprasidone.
EntacaponeThe therapeutic efficacy of Entacapone can be decreased when used in combination with Ziprasidone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ziprasidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ziprasidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ziprasidone.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ziprasidone.
EthanolZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziprasidone.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Ziprasidone.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ziprasidone.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone.
GalantamineGalantamine may increase the central neurotoxic activities of Ziprasidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ziprasidone.
GoserelinGoserelin may increase the QTc-prolonging activities of Ziprasidone.
HydrocodoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziprasidone.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ziprasidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ziprasidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ziprasidone.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Ziprasidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.
IvabradineIvabradine may increase the QTc-prolonging activities of Ziprasidone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ziprasidone.
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Ziprasidone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ziprasidone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone.
LisdexamfetamineZiprasidone may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Ziprasidone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ziprasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziprasidone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ziprasidone.
MethamphetamineZiprasidone may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.
MetyrosineZiprasidone may increase the sedative activities of Metyrosine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Ziprasidone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ziprasidone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ziprasidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ziprasidone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziprasidone.
OctreotideOctreotide may increase the QTc-prolonging activities of Ziprasidone.
OrphenadrineZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydeZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziprasidone.
PhendimetrazineZiprasidone may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.
PhentermineZiprasidone may decrease the stimulatory activities of Phentermine.
PramipexoleThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Ziprasidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziprasidone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziprasidone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ziprasidone.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ziprasidone.
RivastigmineRivastigmine may increase the central neurotoxic activities of Ziprasidone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone.
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Ziprasidone.
RotigotineThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Ziprasidone.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ziprasidone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ziprasidone.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ziprasidone.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
SulpirideThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ziprasidone.
SuvorexantZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineTacrine may increase the central neurotoxic activities of Ziprasidone.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziprasidone.
ThalidomideZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziprasidone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziprasidone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ziprasidone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziprasidone.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ziprasidone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ziprasidone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ziprasidone.
ZolpidemZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Kopecek M, Bares M, Mohr P: Ziprasidone-induced galactorrhea: a case report. Neuro Endocrinol Lett. 2005 Feb;26(1):69-70. [PubMed:15726024 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  6. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Mansbach RS, Carver J, Zorn SH: Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):535-42. [PubMed:11509214 ]
  2. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705 ]
  3. Lu BY, Lundgren R, Escalona PR, Roberts BB: A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry. 2002 Dec;63(12):1185-6. [PubMed:12530423 ]
  4. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G: A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004 May;161(5):818-25. [PubMed:15121646 ]
  5. Kast RE, Focosi D, Petrini M, Altschuler EL: Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant. 2007 Jun;39(12):811-2. Epub 2007 Apr 23. [PubMed:17450180 ]
  6. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  7. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958 ]
  2. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH: 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48(3):229-37. [PubMed:10924666 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268 ]
  5. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ: Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):188-99. Epub 2003 Aug 16. [PubMed:12923612 ]
  6. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  7. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol. 2002 Apr;22(2):206-10. [PubMed:11910268 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  5. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999 Nov;21(5):622-31. [PubMed:10516958 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
  2. Sanchez C, Arnt J: In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol. 2000 Jun;11(3-4):291-8. [PubMed:11103883 ]
  3. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. [PubMed:7562537 ]
  4. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925 ]
  2. Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):106S-115S. [PubMed:10432496 ]
  3. Meltzer HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64-75. [PubMed:7583621 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E: Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol. 2010 Feb;30(1):68-71. doi: 10.1097/JCP.0b013e3181c8273d. [PubMed:20075651 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49 Suppl 1:35S-42S. [PubMed:10771452 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, Kitada M: Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos. 2002 May;30(5):534-40. [PubMed:11950784 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 24, 2016 01:51